PNC Financial Services Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-500
Closed -$1.48K – 4874
2024
Q2
$1.48K Hold
500
– – ﹤0.01% 4335
2024
Q1
$1.46K Hold
500
– – ﹤0.01% 4277
2023
Q4
$1.25K Hold
500
– – ﹤0.01% 4273
2023
Q3
$1.56K Hold
500
– – ﹤0.01% 4295
2023
Q2
$2.3K Hold
500
– – ﹤0.01% 4342
2023
Q1
$3.54K Hold
500
– – ﹤0.01% 4152
2022
Q4
$3.21K Hold
500
– – ﹤0.01% 4132
2022
Q3
$7K Hold
500
– – ﹤0.01% 3882
2022
Q2
$9K Hold
500
– – ﹤0.01% 3846
2022
Q1
$15K Buy
+500
New +$16K ﹤0.01% 3705
2021
Q4
– Sell
-15
Closed -$1K – 4567
2021
Q3
$1K Buy
+15
New +$1.38K ﹤0.01% 4212
2020
Q3
– Sell
-1
Closed – – 4005
2020
Q2
$0 Hold
1
– – ﹤0.01% 4007
2020
Q1
$0 Hold
1
– – ﹤0.01% 4009
2019
Q4
$0 Hold
1
– – ﹤0.01% 4069
2019
Q3
$0 Hold
1
– – ﹤0.01% 4077
2019
Q2
$0 Hold
1
– – ﹤0.01% 4099
2019
Q1
$0 Hold
1
– – ﹤0.01% 4103
2018
Q4
$0 Hold
1
– – ﹤0.01% 4137
2018
Q3
$0 Hold
1
– – ﹤0.01% 4204
2018
Q2
$0 Hold
1
– – ﹤0.01% 4230
2018
Q1
$0 Hold
1
– – ﹤0.01% 4249
2017
Q4
$0 Hold
1
– – ﹤0.01% 4212
2017
Q3
$0 Hold
1
– – ﹤0.01% 4205
2017
Q2
$0 Sell
1
-200
-100% -$22.8K ﹤0.01% 4206
2017
Q1
$24K Hold
201
– – ﹤0.01% 3224
2016
Q4
$28K Hold
201
– – ﹤0.01% 3093
2016
Q3
$20K Hold
201
– – ﹤0.01% 3222
2016
Q2
$14K Hold
201
– – ﹤0.01% 3403
2016
Q1
$18K Buy
+201
New +$17.8K ﹤0.01% 3331

Other funds holding IMDX

PNC Financial Services Group's IMDX Position: Q3 2024 in Review

PNC Financial Services Group sold out of Insight Molecular Diagnostics (IMDX) in Q3 2024, closing a stake of 500 shares — an estimated $1.48K sold.

PNC Financial Services Group first reported a position in IMDX in Q1 2016 and held it in 29 quarters. The position peaked at $28K in Q4 2016. 21 funds tracked by Wall St. Rank hold IMDX as of Q3 2024.

  • PNC Financial Services Group reported no remaining Insight Molecular Diagnostics position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 500 Insight Molecular Diagnostics shares in Q3 2024, an estimated $1.48K.
  • PNC Financial Services Group first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 29 quarters.
  • PNC Financial Services Group's Insight Molecular Diagnostics position peaked at $28K in Q4 2016.
  • 21 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.